Neuroprotection in Parkinson disease

Archives of Internal Medicine

Volumn 163, Issue 14, 2003, Pages 1650-1654

  Simpkins, Nicole ^b   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ALPHA TOCOPHEROL; AMANTADINE; BROMOCRIPTINE; CASPASE INHIBITOR; CATALASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTATHIONE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOMODULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; SUPEROXIDE DISMUTASE; TCH 346; UNCLASSIFIED DRUG;

APOPTOSIS; BRAIN DEPTH STIMULATION; CHOREA; CLINICAL TRIAL; DELUSION; DISEASE COURSE; DYSKINESIA; DYSTONIA; EARLY DIAGNOSIS; HALLUCINATION; HUMAN; MORTALITY; MOTOR DYSFUNCTION; NAUSEA; NERVE DEGENERATION; NEUROPROTECTION; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PALLIDOTOMY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FOLDING; REVIEW; SEXUAL DYSFUNCTION; SYMPTOM; TACHYCARDIA; VOMITING;

CELL DEATH; DISEASE PROGRESSION; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 0042809823     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.14.1650     Document Type: Review

References (30)

1. Fearnley J, Lees A. Aging and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114:2283-2301.
2. Kraus P. Early diagnosis in Parkinson's disease: limitation of biochemical markers and instrumental methods. J Neural Transm Suppl. 1996;48:23-28.
3. Brooks D. The early diagnosis of Parkinson's disease. Ann Neurol. 1998;44(suppl 1):S10-S18.
4. Przuntek H. Early diagnosis in Parkinson's disease. J Neural Transm Suppl. 1992;38:105-114.
5. Gonera EG, van't Hof M, Berger HJC, et al. Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord. 1997;12:871-876.
6. Montgomery E, Koller W, LaMantia T, et al. Early detection of probable idiopathic Parkinson's disease: development of a diagnostic test battery. Mov Disord. 2000;15:467-473.
7. Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann Neurol. 2003;53(suppl 3):S110-S119.
8. Tissingh G, Bergmans P, Booij J, et al. Drug-naïve patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]β-CIT SPECT. J Neurol. 1998;245:14-20.
9. Tedroff J, Ekesbo A, Rydin E, Langstrom B, Hagberg G. Regulation of dopaminergic activity in early Parkinson's disease. Ann Neurol. 1999;46:359-365.
10. Olanow CW, Tatton WG, Jenner P. Mechanisms of cell death in Parkinson's disease. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. 4th ed. Philadephia, Pa: Lippincott Williams & Wilkins; 2002.
11. Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002;58(suppl 1):S19-S32.
12. Zou L, Jankovic J, Rowe DB, Xie W, Appel SH, Le W. Neuroprotection by pramipexole against dopamine-and levodopa-induced cytotoxicity. Life Sci. 1999;64:1275-1285.
13. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol. 2003;53(suppl 3):S26-S38.
14. Giladi N, McDermott MP, Fahn S, Przedborski S, Jankovic J, Stern M, Tanner C, and the Parkinson Study Group. Freezing of gait in PD: progressive assessment of the DATATOP cohort. Neurology. 2001;56:1712-1721.
15. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of Parkinsonism trial. Ann Neurol. 2002;51:604-612.
16. Olanow C, Myllyla V, Sotaniemi K, et al. Effect of selegiline on mortality in patients with Parkinson's disease. Neurology. 1998;51:825-830.
17. Grunblatt E, Mendel S, Youdim M. Neuroprotective strategies in PD using the models of 6-hydroxydopamine and MPTP. Ann N Y Acad Sci. 2000;899:262-273.
18. Waldmeier PC, Boulton AA, Cools AR, et al. Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural Transm Suppl. 2000;60:197-214.
19. Le W, Jankovic J, Xie W, Appel S. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm. 2000;107:1165-1173.
20. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2003;60:381-389.
21. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 1999;838:51-59.
22. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653-1661.
23. Whone AL, Remy P, Davis MR, et al. The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared to L-dopa. Neurology. 2002;58(suppl 3):A82-A83.
24. Uitti RJ, Rajput A, Ahlskog J, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology. 1996;46:1551-1556.
25. Verhagen Metman L, Dotto PD, LePoole K, et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol. 1999;56:1383-1386.
26. Jankovic J. New and emerging therapies for Parkinson disease. Arch Neurol. 1999;56:785-790.
27. Kitamura Y, Kakimura J, Taniguchi T. Antiparkinsonian drugs and their neuroprotective effects. Biol Pharm Bull. 2002;25:284-290.
28. Tintner R, Jankovic J. Treatment options for Parkinson's disease. Curr Opin Neurol. 2002;15:467-476.
29. Jankovic J. Therapeutic strategies in Parkinson's disease. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002:116-151.
30. Jankovic J. Surgery for Parkinson's disease and other movement disorders: benefits and limitations of ablation, stimulation, restoration, and radiation. Arch Neurol. 2001;58:1970-1972.